JP2021520831A5 - - Google Patents

Info

Publication number
JP2021520831A5
JP2021520831A5 JP2020556864A JP2020556864A JP2021520831A5 JP 2021520831 A5 JP2021520831 A5 JP 2021520831A5 JP 2020556864 A JP2020556864 A JP 2020556864A JP 2020556864 A JP2020556864 A JP 2020556864A JP 2021520831 A5 JP2021520831 A5 JP 2021520831A5
Authority
JP
Japan
Prior art keywords
chain
tcr
seq
treg
acid sequence
Prior art date
Application number
JP2020556864A
Other languages
English (en)
Japanese (ja)
Other versions
JP7436383B2 (ja
JP2021520831A (ja
JPWO2019202322A5 (https=
Filing date
Publication date
Priority claimed from GBGB1806331.3A external-priority patent/GB201806331D0/en
Priority claimed from GBGB1806330.5A external-priority patent/GB201806330D0/en
Application filed filed Critical
Priority claimed from PCT/GB2019/051097 external-priority patent/WO2019202322A1/en
Publication of JP2021520831A publication Critical patent/JP2021520831A/ja
Publication of JP2021520831A5 publication Critical patent/JP2021520831A5/ja
Publication of JPWO2019202322A5 publication Critical patent/JPWO2019202322A5/ja
Application granted granted Critical
Publication of JP7436383B2 publication Critical patent/JP7436383B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020556864A 2018-04-18 2019-04-17 操作された調節性ｔ細胞 Active JP7436383B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1806331.3 2018-04-18
GBGB1806331.3A GB201806331D0 (en) 2018-04-18 2018-04-18 Method
GB1806330.5 2018-04-18
GBGB1806330.5A GB201806330D0 (en) 2018-04-18 2018-04-18 Engineered regulatory T cell
PCT/GB2019/051097 WO2019202322A1 (en) 2018-04-18 2019-04-17 Engineered regulatory t cell

Publications (4)

Publication Number Publication Date
JP2021520831A JP2021520831A (ja) 2021-08-26
JP2021520831A5 true JP2021520831A5 (https=) 2022-03-31
JPWO2019202322A5 JPWO2019202322A5 (https=) 2022-03-31
JP7436383B2 JP7436383B2 (ja) 2024-02-21

Family

ID=66286535

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020556883A Active JP7391038B2 (ja) 2018-04-18 2019-04-17 Ｔｒｅｇ細胞の抑制特性を増強するための方法
JP2020556864A Active JP7436383B2 (ja) 2018-04-18 2019-04-17 操作された調節性ｔ細胞
JP2023197319A Active JP7839774B2 (ja) 2018-04-18 2023-11-21 Ｔｒｅｇ細胞の抑制特性を増強するための方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020556883A Active JP7391038B2 (ja) 2018-04-18 2019-04-17 Ｔｒｅｇ細胞の抑制特性を増強するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023197319A Active JP7839774B2 (ja) 2018-04-18 2023-11-21 Ｔｒｅｇ細胞の抑制特性を増強するための方法

Country Status (11)

Country Link
US (4) US12227756B2 (https=)
EP (2) EP3781672B1 (https=)
JP (3) JP7391038B2 (https=)
KR (1) KR20210003810A (https=)
CN (2) CN112334571B (https=)
AU (2) AU2019254824B2 (https=)
CA (2) CA3105303A1 (https=)
GB (3) GB2611498B (https=)
IL (1) IL278016B2 (https=)
SG (1) SG11202010154UA (https=)
WO (2) WO2019202322A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019254824B2 (en) 2018-04-18 2025-04-24 Ucl Business Ltd Method for enhancing the suppressive properties of Treg cells
EP3921427A1 (en) * 2019-02-05 2021-12-15 Institut National de la Santé et de la Recherche Médicale (INSERM) Recombinant vectors suitable for the treatment of ipex syndrome
GB201915359D0 (en) * 2019-10-23 2019-12-04 Ucl Business Ltd Engineered regulatory t cell
PL241050B1 (pl) * 2019-12-12 2022-07-25 Gdanski Univ Medyczny Zastosowanie limfocytów T regulatorowych jako leku w leczeniu stwardnienia rozsianego
EP4240376B1 (en) * 2020-11-09 2026-03-25 Quell Therapeutics Limited Method for cryopreserving engineered tregs
US20220169687A1 (en) * 2020-11-10 2022-06-02 Kyverna Therapeutics, Inc. Method for treating disease using foxp3+cd4+ t cells
WO2022165419A1 (en) 2021-02-01 2022-08-04 Kyverna Therapeutics, Inc. Methods for increasing t-cell function
US20240400993A1 (en) * 2021-09-27 2024-12-05 Kyoto University Method for producing t cell
US20250017967A1 (en) 2021-12-17 2025-01-16 Quell Therapeutics Limited Anti-thymocyte globulin for immunomodulation of a subject with regulatory t cells
US20230210900A1 (en) * 2022-01-04 2023-07-06 Kyverna Therapeutics, Inc. Methods for treating autoimmune diseases
WO2023180690A1 (en) 2022-03-22 2023-09-28 Quell Therapeutics Limited Methods and products for culturing t cells and uses thereof
EP4519417A1 (en) * 2022-05-05 2025-03-12 Quell Therapeutics Limited Method for maintaining suppressive activity of regulatory t cells
CN116284447A (zh) * 2023-02-20 2023-06-23 苏州大学 一种靶向pd1嵌合抗原受体修饰的调节性t细胞及其制备方法与应用
EP4680728A1 (en) 2023-03-17 2026-01-21 Quell Therapeutics Limited Treg therapy

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
MD1367C2 (ro) 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
GB9803351D0 (en) 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
EP1105479B1 (en) 1998-08-11 2011-01-12 Darwin Discovery Limited Identification of the gene causing the mouse scurfy phenotype and its human ortholog
GB0009760D0 (en) 2000-04-19 2000-06-07 Oxford Biomedica Ltd Method
US7507542B2 (en) 2001-05-08 2009-03-24 Ucb Sa Method for regulating immune function using the FOXP3 protein
FR2825261B1 (fr) 2001-06-01 2003-09-12 Maco Pharma Sa Ligne de prelevement du sang placentaire comprenant une poche de rincage
WO2005001048A2 (en) 2003-06-13 2005-01-06 Oncomax Acquisition Corp. Preparation and application of anti-tumor bifunctional fusion proteins
CA2529945A1 (en) 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
CA2575604A1 (en) 2004-07-30 2006-02-02 Oregon Health And Science University Methods for detecting and treating autoimmune disorders
US7147626B2 (en) 2004-09-23 2006-12-12 Celgene Corporation Cord blood and placenta collection kit
MX2007014673A (es) 2005-05-24 2008-04-08 Avestha Gengraine Tech Pvt Ltd Metodo para la produccion de un anticuerpo monoclonal para cd20 para el tratamiento de linfoma de celular b.
EP2126054B1 (en) * 2007-01-31 2016-07-06 Yeda Research And Development Company Limited Redirected, genetically-engineered t regulatory cells and their use in suppression of autoimmune and inflammatory disease
EP2050814A1 (en) 2007-10-17 2009-04-22 Txcell Compositions for treating multiple sclerosis
JP5626164B2 (ja) 2011-07-26 2014-11-19 日本精工株式会社 ステアリングコラム用支持装置
US20150073043A1 (en) 2012-01-19 2015-03-12 Institut Pasteur Of Shanghai, Chinese Academy Of Sciences Use of phosphorylation pathway-related factor in regulating function of regulatory t cell
RU2523058C2 (ru) 2012-06-29 2014-07-20 Общество с ограниченной ответственностью "Регенекс" Способ терапии ремиттирующего рассеянного склероза
US9693977B2 (en) 2013-03-15 2017-07-04 President And Fellows Of Harvard College Method of increasing the quantity of colonic T regulatory cells via G-coupled protein receptor 43
WO2014183056A1 (en) 2013-05-10 2014-11-13 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Design and use of specific regulatory t-cells to induce immune tolerance
GB201322430D0 (en) 2013-12-18 2014-02-05 Immunocore Ltd T cell receptors
HK1245827B (en) 2014-12-15 2020-06-19 Board Of Regents Of The University Of Texas System Methods for controlled activation or elimination of therapeutic cells
EP3259284B1 (en) 2015-02-16 2020-04-01 The Trustees of the University of Pennsylvania A fully-human t cell receptor specific for the 369-377 epitope derived from the her2/neu (erbb2) receptor protein
GB201507368D0 (en) * 2015-04-30 2015-06-17 Ucl Business Plc Cell
WO2017058752A1 (en) 2015-09-28 2017-04-06 Trustees Of Dartmouth College Chimeric antigen receptor anti-inflammatory cells and methods of use
WO2017062035A1 (en) 2015-10-09 2017-04-13 Abt Holding Company Methods for enhancing proliferation of t regulatory cells
US10604586B2 (en) 2016-05-09 2020-03-31 Industrial Technology Research Institute Humanized monoclonal antibody and uses thereof
CN109476749A (zh) 2016-06-30 2019-03-15 豪夫迈·罗氏有限公司 改良的过继性t细胞疗法
EP3714944A1 (en) 2019-03-29 2020-09-30 Medizinische Hochschule Hannover Car for use in the treatment of hvg disease
EP3263595A1 (en) * 2016-06-30 2018-01-03 Medizinische Hochschule Hannover Fusion protein for use in the treatment of hvg disease
SG11201912010XA (en) 2017-06-12 2020-01-30 Obsidian Therapeutics Inc Pde5 compositions and methods for immunotherapy
WO2018236909A1 (en) 2017-06-20 2018-12-27 La Jolla Institute For Allergy And Immunology Engineered t-cell receptors and methods of their use in modulating inflammatory responses and treating atherosclerosis
EP3697820A4 (en) 2017-10-17 2022-01-05 The General Hospital Corporation PROCEDURES AND COMPOSITIONS RELATED TO MANIPULATED REGULATORY T-CELLS
AU2019254824B2 (en) 2018-04-18 2025-04-24 Ucl Business Ltd Method for enhancing the suppressive properties of Treg cells
WO2019241549A1 (en) 2018-06-15 2019-12-19 A2 Biotherapeutics, Inc. Foxp3-expressing car-t regulatory cells
GB201814203D0 (en) 2018-08-31 2018-10-17 King S College London Engineered regulatory t cell
EP3973067A1 (en) 2019-05-21 2022-03-30 Sangamo Therapeutics, Inc. Controlled transgene expression in regulatory t cells
GB201915359D0 (en) * 2019-10-23 2019-12-04 Ucl Business Ltd Engineered regulatory t cell
GB201915384D0 (en) 2019-10-23 2019-12-04 Ucl Business Ltd Vector
GB202007842D0 (en) 2020-05-26 2020-07-08 Quell Therapeutics Ltd Polypeptide useful in adoptive cell therapy

Similar Documents

Publication Publication Date Title
JP2021520831A5 (https=)
US12297252B2 (en) T cell receptors with improved pairing
JP2021520198A5 (https=)
JP2022502371A5 (https=)
BR112022001923A2 (pt) Proteína de ligação ao antígeno, ácido nucleico isolado, célula hospedeira recombinante, composição farmacêutica, método de produção da proteína de ligação ao antígeno
JP2022050400A5 (https=)
JP2020500523A5 (https=)
JP2021526816A5 (https=)
JP2020537515A5 (https=)
FI4219542T3 (fi) T-solureseptoreja
JP2019511222A5 (https=)
JP2019536430A5 (https=)
JP2019536437A5 (https=)
JPWO2019202322A5 (https=)
JP2018510881A5 (https=)
JPWO2020069028A5 (https=)
JPWO2020059847A5 (https=)
JPWO2019195486A5 (https=)
JPWO2020063488A5 (https=)
JP2017505621A5 (https=)
JP2025063321A5 (https=)
JP2021505190A5 (https=)
JPWO2020071554A5 (https=)
US20250163124A1 (en) T cell receptors with improved pairing
JP2020509745A5 (https=)